Aptargroup Inc
ATR
ISIN null / Valor 68947
Aptargroup Inc
UMushroom community rating:
About company
Aptargroup Inc., headquartered in Crystal Lake, Illinois, operates as a prominent provider in the realm of drug delivery systems, consumer product dispensing, and active material science solutions. With a workforce of over 13,000 employees spread across 20 countries, the company caters to a diverse range of industries including pharmaceuticals, beauty, food and beverage, personal care, and home care. Aptargroup's business model is centered around innovation and adaptability, ensuring that both the company and its clients' products remain relevant in the face of changing market demands. By offering specialized services and products in drug delivery and consumer product dispensing, Aptargroup plays a crucial role in enhancing the functionality and user experience of a wide array of consumer goods and pharmaceuticals.
Summarized from source with an LLMView SourceSector: IndustrialsLatest Results (23.09.2025):
AptarGroup Inc. reported strong financial results for the third quarter of 2024, showcasing solid operational performance and margin improvements. The company's growth was primarily driven by its proprietary drug delivery systems and increased demand for closure technologies, resulting in a significant increase in net income compared to the previous year.
Sales Growth
Reported and core sales for AptarGroup Inc. increased by 2% in the third quarter of 2024, reaching $909 million. This growth was driven by an 8% increase in the Pharma segment and a 3% rise in the Closures segment, while the Beauty segment experienced a 7% decline.
Earnings and Profitability
The company achieved a net income of $100 million for the quarter, marking a 19% increase from the prior year. Additionally, reported earnings per share rose by 17% to $1.48, and adjusted earnings per share increased by 6% to $1.49. The adjusted EBITDA also saw an 8% growth, reaching $208 million with a margin of 23%.
Segment Performance
The Pharma segment showed robust performance with an 8% increase in reported sales and a 7% rise in core sales, driven by high demand for proprietary drug delivery systems. The Closures segment maintained steady growth, aligning with long-term target ranges. Conversely, the Beauty segment faced challenges, with reported sales declining by 7% due to less favorable comparisons from the previous year.
Cash Flow and Financial Health
For the first nine months of 2024, AptarGroup Inc. reported a 3% increase in sales to $2.73 billion and a double-digit growth in earnings per share. Net cash provided by operations rose to $465 million, and free cash flow increased to $255 million, reflecting improved financial stability.
Strategic Initiatives and Outlook
AptarGroup Inc. strengthened its dispensing technology footprint by closing a joint venture transaction in China. The company anticipates continued growth in the fourth quarter of 2024 and is positioned to achieve double-digit adjusted EPS growth for the full year. The ongoing focus on innovation, cost mitigation, and operational efficiencies is expected to drive future performance.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
8564 M
Market cap (USD)
240,513
Daily traded volume (Shares)
157.49 / 155.11
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
